期刊文献+

热休克蛋白65-MUC1抗原肽融合蛋白效力测定方法的建立 被引量:2

Development of A Method for Determination of Potency of Heat Shock Protein 65-MUC1 Antigen Peptide Fusion Protein
下载PDF
导出
摘要 目的建立热休克蛋白65(HSP65)MUC1抗原肽(HSP65MUC1)融合蛋白的效力测定方法。方法从人外周血中分离出单核细胞,并用人IL4和GMCSF将其诱导为未成熟的树突状细胞(iDCs),将HSP65MUC1融合蛋白加载至iDC中继续培养2d后,用流式细胞仪检测树突状细胞(DCs)表面CD80、CD83和CD86等的表达。结果HSP65MUC1融合蛋白能使iDCs表面的CD80、CD83和CD86等表达上调,其中CD86的表达上调程度与其加载HSP65MUC1融合蛋白的量成正相关。结论通过检测对人iDCs表面CD86表达的刺激作用来检测HSP65MUC1融合蛋白效力的实验方法具有操作简便、周期短和重复性好等优点。 Objective To develop a method for determining the potency of heat shock protein 65-MUC1 antigen peptide fusion protein(HSP65-MUC1).Methods Immature dendritic cells(iDCs) were derived from human PBMC by induction with human IL-4 and GM-CSF.Add HSP65-MUC1 fusion protein into iDC and incubate for 2 days.Determine the expressions of CD80,CD83 and CD86 on the surface of DCs by flow cytometer.Results HSP65-MUC1 fusion protein enhanced the expressions of CD80,CD83 and CD86.The up-regulation of CD86 was positively related to the amount of HSP65-MUC1 added into iDCs.Conclusion A method for determining the potency of HSP65-MUC1 fusion protein by testing the expression of CD86 on the surface of iDCs was developed.The method was simple,time-saving and of good reproducibility.
出处 《中国生物制品学杂志》 CAS CSCD 2005年第4期332-335,共4页 Chinese Journal of Biologicals
基金 国家"八六三"计划资助(批准号:2002AA214141
关键词 热休克蛋白 MUC1蛋白 抗原肽 融合蛋白 效力 测定方法 树突状细胞 肿瘤 免疫治疗 Heat shock protein MUC1 Fusion protein Dendritic cells CD86
  • 相关文献

参考文献8

  • 1Dekker J, Rossen JW, Buller HA, et al. The MUC family:an obituary.Trends Biochem Sci Mar,2002,27(3): 126-131.
  • 2Lagow E, DeSouza MM, Carson DD. Mammalian reproductive tract mucins. Hum Reprode Update, 1999,5:280-292.
  • 3Brossart P, Schneider A,Dill P,et al. The epithelial tumor antigen MUC1is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. Cancer Res,2001,61:6846-6850.
  • 4Somersan S,Larsson M,Fonteneau JF,et al. Primary tumor tissue lysates are enriched in heat shock proteins and induce the maturation of human dendritic cells. J Immunology,2001,167:4844-4852.
  • 5Kuppner MC, Gastpar R, Gelwer S, et al. The role of heat shock protein (Hsp70) in dendritic cell maturation: Hsp70 induces the maturation of immature dendritic cells but reduces DC differentiation from monocyte precursors. Eur J Immunol,2001,31:1602-1609.
  • 6Thumann P, Moc I, Humrich J, et al. Antigen loading of dendritic cells with whole tumor cell preparations. J Immunol Methods,2003,277:1-16.
  • 7Feuerstein B, Berger TG, Maczek C,et al.A method for the production of cryopreserved aliquots of antigen-preloaded, mature dendritic cells ready for clinical use. J Immunol Methods,2000,245:15-29.
  • 8McLellan AD, Starling GC, Williams LA, et al. Activation of human peripheral blood dendritic cells induces the CD86 co-stimulatory molecule.Eur J Immunol, 1995,25(7) :2064-2068.

同被引文献26

  • 1李波.安全药理学的国内外发展概况[J].中国新药杂志,2004,13(11):964-968. 被引量:8
  • 2梁昊宇,曾明.新疫苗和佐剂的临床前安全性评价[J].国际生物制品学杂志,2006,29(4):163-165. 被引量:7
  • 3梁昊宇,曾明.新疫苗和佐剂的临床前安全性评价(续)[J].国际生物制品学杂志,2006,29(5):202-205. 被引量:2
  • 4程晓丽,神吉智丈,李春燕,金秀日,康東天.热休克蛋白10和热休克蛋白的60表达、纯化及与线粒体DNA转录因子A相互结合[J].郑州大学学报(医学版),2007,42(1):50-52. 被引量:5
  • 5孟淑芳.肿瘤疫苗与肿瘤诊断试剂[A].王军志.生物技术药物研究开发和质量控制[M].北京:科学出版社,2002:685-689.
  • 6Brennan FR, Shaw L, Wing MG, et testing of biot echnology-derived al. Preclinical safety pharmaceuticals : understanding the issues and addressing the challenges[J]. Mol Biotechnol, 2004, 27(1): 59-74.
  • 7Li D, Li H, Zhang P, et al. Heat shock fusion protein induces both specific and nonspecific anti-tumor imnmnity[J]. Eur J Immunol, 2006, 36 (5): 1324-1336.
  • 8Abulafia Lapid R, Elias D, Raz I, et al. T cell proliferative responses of type 1 diabetes patients and healthy individuals to human HSP60 and its peptides [J]. Autoimmunity, 1999,12(2): 121-129.
  • 9Chen K, Lu J, Wang L, et al. Mycohacterial heat shock protein 65 enhance antigen cross presentation in dendritic cells independent of Toll-like receptor 4 signaling[J]. Leukoc Biol, 2004, 75(2): 260-266.
  • 10Huo Y, Li B, Zhang Y, et al. Pre-clinical safety evaluation of heat shock protein 65-MUClpeptide fusion protein[J]. Regulat ToxicolPharmacol, 2007, 49(1): 63-74.

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部